Tech Company Financing Transactions
Envisagenics Funding Round
Envisagenics closed a Series A financing round on 10/5/2021. Investors included Red Cell Partners, Dynamk Capital and Empire State Development.
Transaction Overview
Company Name
Announced On
10/5/2021
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Red Cell Partners (Lead Investor) (Grant Verstandig)
Proceeds Purpose
The company intends to use the funds to scale its drug discovery platform and biopharmaceutical partnerships.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
101 Ave. of the Americas 3rd Floor
New York, NY 10013
USA
New York, NY 10013
USA
Phone
Website
Email Address
Overview
Envisagenics is a New York City-based a bioinformatics company. Biomedical data might hold the key to finding the cure for currently incurable diseases. Our mission is to reduce the complexity of RNA-seq data into plausible candidates for drug and biomarker development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maria Pineda
Chief Technical Officer
Martin Akerman
Browse more venture capital transactions:
Prev: 10/5/2021: Ziply Fiber venture capital transaction
Next: 10/5/2021: Ladder Insurance venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs